By using in silico computer-aided drug design approaches, the activity of biaryl compounds against AD targets BACE1 and BACE2 was also determined and interestingly it was found that the fused-ring compounds are in general more active than the biaryl-based ligands [32]. The gene discussed is BACE1; the disease is Alzheimer disease.